Article Contents ::

Details About Generic Salt ::  Denileu1

Main Medicine Class::    

(duh-nih-LOO-kin DIFF-tih-tox)
Ontak
Frozen, solution for injection
150 mcg/mL
Class: Biologic response modifier

 Indications Cutaneous T-cell lymphoma.

 Contraindications Standard considerations.

 Route/Dosage

Cutaneous T-Cell lLymphoma

ADULTS: IV 1 treatment cycle is 9 or 18 mcg/kg/day administered for 5 consecutive days q 21 days. Infuse over at least 15 min.

Pretreatment Regimen

ADULTS: Give acetaminophen 650 mg (PO or rectal) and diphenhydramine 25 to 50 mg (PO or IV) 30 to 60 min before administering denileukin diftitox.

Dosage Adjustments

ADULTS: Delay therapy in patients with serum albumin below 3 g/dL.

Interactions

Beta blockers, other antihypertensive

May exacerbate denileukin diftitox-induced hypotension.

Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Capillary leak syndrome; hypotension; edema; chest pain; tachycardia; thrombotic events; MI. CNS: Asthenia; headache; dizziness; paresthesia; nervousness; confusion; insomnia. DERMATOLOGIC: Rash; pruritus; injection site irritation. ENDOCRINE: Hypoalbuminemia; infection; impaired immune function; hypocalcemia; albuminuria. GI: Nausea; vomiting; elevated LFTs; anorexia; diarrhea; constipation; weight loss; dysphagia. GU: Hematuria; pyuria. HEMATOLOGIC: Anemia; thrombocytopenia; leukopenia. HYPERSENSITIVITY: Hypotension; dyspnea; vasodilation; rash; pruritis; anaphylaxis. METABOLIC: Dehydration. MUSCULOSKELETAL: Myalgia; arthralgia; pain. RENAL: Hematuria; pyuria; increased serum creatinine. RESPIRATORY: Dyspnea; cough increase; pharyngitis; rhinitis. OTHER: Chills; fever.

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Patients receiving denileukin should discontinue nursing. Children: Safety and efficacy not established. Elderly: Anorexia, hypotension, anemia, confusion, rash, nausea, or vomiting tended to be more frequent or severe in patients at least 65 yr. Hypersensitivity: Acute hypersensitivity reactions were reported in 69% of patients during or within 24 hr of infusion; about 50% of the events occurred on the first day of dosing regardless of the treatment cycle. Vascular leak syndrome: Occurs within 2 wk after starting therapy. Take special caution in patients with preexisting cardiovascular disease.

PATIENT CARE CONSIDERATIONS


 Administration/Storage

  • Administer by IV use only. Do not administer as a bolus injection. Do not physically mix with other drugs. Do not administer through an in-line filter.
  • Dilute the desired dose with 0.9% Sodium Chloride for a final concentration of at least 15 mcg/mL. The denileukin diftitox concentration should not be under 15 mcg/mL at any time during prouct preparation. Swirl vial gently to mix the solution. Do not shake vial.
  • Administer prepared solutions within 6 hr, using a syringe pump or IV infusion bag.
  • Discard unused portions immediately.
  • Store frozen at no more than -10°C (14°F). Must be brought to room temperature, at no more than 25°C (77°F), before preparing the dose. The vials may be thawed in the refrigerator at 2° to 8°C (36° to 46°F) for no more than 24 hr or at room temperature for 1 to 2 hr. Do not heat denileukin. Do not refreeze.
  • Do not use glass IV containers.

 Assessment/Interventions

  • Denileukin diftitox should be used only by health care providers experienced in the use of antineoplatic therapy and management of patients with cancer. Manage patients treated with denileukin diftitox in a facility equipped and staffed for cardiopulmonary resuscitation and where the patient can be closely monitored for an appropriate period based on his or her health status.
  • Prior to administration of this product, test the patient’s malignant cells for CD25 expression.
  • Perform a CBC and a blood chemistry panel, including liver and renal function and serum albumin levels, prior to initiation of treatment and weekly during therapy.
  • Monitor serum albumin levels prior to the initiation of each treatment course. Delay administration until serum albumin levels are at least 3 g/dL.
  • Carefully monitor weight, edema, BP, urine output, and serum albumin levels on an outpatient basis.
  • Carefully monitor patients for infections.

 Patient/Family Education

  • Explain name, action, and potential side effects of drug.
  • Advise patient, family, or caregiver that medication will be prepared and administered by health care provider in a health care setting.
  • Review dosing schedule with patient, family, or caregiver.
  • Advise patient, family, or caregiver that home blood pressure measurements and weighing may be necessary. Instruct patient, family, or caregiver in proper technique if necessary.
  • Advise patient, family, or caregiver to immediately report any of the following to health care provider: rash; hives; flushing; difficulty breathing; chest pain or tightness; back pain; difficulty swallowing; fainting; swelling; fever, chills, or other signs of infection; sores in mouth; unusual bleeding or bruising.
  • Advise patient, family, or caregiver to report any of the following to health care provider: persistent nausea, vomiting, diarrhea or appetite loss; persistent or worsening general body weakness; pain, redness, or swelling at injection site.
  • Instruct patient to not take any prescription or otc medications or dietary supplements unless advised to do so by health care provider.
  • Instruct women of childbearing potential to notify health care provider if becoming pregnant, planning on becoming pregnant, or are breastfeeding.
  • Advise patient that frequent follow-up visits and laboratory tests will be required to monitor therapy and to keep appointments.

Medicscientist Drug Facts

 

Drugs Class ::

(duh-nih-LOO-kin DIFF-tih-tox)
Ontak
Frozen, solution for injection
150 mcg/mL
Class: Biologic response modifier

Indications for Drugs ::

 Indications Cutaneous T-cell lymphoma.

Drug Dose ::

 Route/Dosage

Cutaneous T-Cell lLymphoma

ADULTS: IV 1 treatment cycle is 9 or 18 mcg/kg/day administered for 5 consecutive days q 21 days. Infuse over at least 15 min.

Pretreatment Regimen

ADULTS: Give acetaminophen 650 mg (PO or rectal) and diphenhydramine 25 to 50 mg (PO or IV) 30 to 60 min before administering denileukin diftitox.

Dosage Adjustments

ADULTS: Delay therapy in patients with serum albumin below 3 g/dL.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Patients receiving denileukin should discontinue nursing. Children: Safety and efficacy not established. Elderly: Anorexia, hypotension, anemia, confusion, rash, nausea, or vomiting tended to be more frequent or severe in patients at least 65 yr. Hypersensitivity: Acute hypersensitivity reactions were reported in 69% of patients during or within 24 hr of infusion; about 50% of the events occurred on the first day of dosing regardless of the treatment cycle. Vascular leak syndrome: Occurs within 2 wk after starting therapy. Take special caution in patients with preexisting cardiovascular disease.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Capillary leak syndrome; hypotension; edema; chest pain; tachycardia; thrombotic events; MI. CNS: Asthenia; headache; dizziness; paresthesia; nervousness; confusion; insomnia. DERMATOLOGIC: Rash; pruritus; injection site irritation. ENDOCRINE: Hypoalbuminemia; infection; impaired immune function; hypocalcemia; albuminuria. GI: Nausea; vomiting; elevated LFTs; anorexia; diarrhea; constipation; weight loss; dysphagia. GU: Hematuria; pyuria. HEMATOLOGIC: Anemia; thrombocytopenia; leukopenia. HYPERSENSITIVITY: Hypotension; dyspnea; vasodilation; rash; pruritis; anaphylaxis. METABOLIC: Dehydration. MUSCULOSKELETAL: Myalgia; arthralgia; pain. RENAL: Hematuria; pyuria; increased serum creatinine. RESPIRATORY: Dyspnea; cough increase; pharyngitis; rhinitis. OTHER: Chills; fever.

Drug Mode of Action ::  

(duh-nih-LOO-kin DIFF-tih-tox)
Ontak
Frozen, solution for injection
150 mcg/mL
Class: Biologic response modifier

Drug Interactions ::

Interactions

Beta blockers, other antihypertensive

May exacerbate denileukin diftitox-induced hypotension.

Drug Assesment ::

 Assessment/Interventions

  • Denileukin diftitox should be used only by health care providers experienced in the use of antineoplatic therapy and management of patients with cancer. Manage patients treated with denileukin diftitox in a facility equipped and staffed for cardiopulmonary resuscitation and where the patient can be closely monitored for an appropriate period based on his or her health status.
  • Prior to administration of this product, test the patient’s malignant cells for CD25 expression.
  • Perform a CBC and a blood chemistry panel, including liver and renal function and serum albumin levels, prior to initiation of treatment and weekly during therapy.
  • Monitor serum albumin levels prior to the initiation of each treatment course. Delay administration until serum albumin levels are at least 3 g/dL.
  • Carefully monitor weight, edema, BP, urine output, and serum albumin levels on an outpatient basis.
  • Carefully monitor patients for infections.

Drug Storage/Management ::

 Administration/Storage

  • Administer by IV use only. Do not administer as a bolus injection. Do not physically mix with other drugs. Do not administer through an in-line filter.
  • Dilute the desired dose with 0.9% Sodium Chloride for a final concentration of at least 15 mcg/mL. The denileukin diftitox concentration should not be under 15 mcg/mL at any time during prouct preparation. Swirl vial gently to mix the solution. Do not shake vial.
  • Administer prepared solutions within 6 hr, using a syringe pump or IV infusion bag.
  • Discard unused portions immediately.
  • Store frozen at no more than -10°C (14°F). Must be brought to room temperature, at no more than 25°C (77°F), before preparing the dose. The vials may be thawed in the refrigerator at 2° to 8°C (36° to 46°F) for no more than 24 hr or at room temperature for 1 to 2 hr. Do not heat denileukin. Do not refreeze.
  • Do not use glass IV containers.

Drug Notes ::

 Patient/Family Education

  • Explain name, action, and potential side effects of drug.
  • Advise patient, family, or caregiver that medication will be prepared and administered by health care provider in a health care setting.
  • Review dosing schedule with patient, family, or caregiver.
  • Advise patient, family, or caregiver that home blood pressure measurements and weighing may be necessary. Instruct patient, family, or caregiver in proper technique if necessary.
  • Advise patient, family, or caregiver to immediately report any of the following to health care provider: rash; hives; flushing; difficulty breathing; chest pain or tightness; back pain; difficulty swallowing; fainting; swelling; fever, chills, or other signs of infection; sores in mouth; unusual bleeding or bruising.
  • Advise patient, family, or caregiver to report any of the following to health care provider: persistent nausea, vomiting, diarrhea or appetite loss; persistent or worsening general body weakness; pain, redness, or swelling at injection site.
  • Instruct patient to not take any prescription or otc medications or dietary supplements unless advised to do so by health care provider.
  • Instruct women of childbearing potential to notify health care provider if becoming pregnant, planning on becoming pregnant, or are breastfeeding.
  • Advise patient that frequent follow-up visits and laboratory tests will be required to monitor therapy and to keep appointments.

Medicscientist Drug Facts

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

DOWNLOAD OUR ANDROID APP

One of the 1st in India.High Quality Generic Medicine Portal Android Application for Online Oreder & Information.

For More Join Our Membership and Get Additional 25% off on Meds, also get MLM Benefits to get a permanent earning source.

Join Membership How to Search Medicine
Android App

We would like to keep you updated with special notifications.